X0306 4 2020-06-19 0 0001521036 Lantheus Holdings, Inc. LNTH 0001788919 Maeusli Heinz Christoph C/O LANTHEUS HOLDINGS, INC. 331 TREBLE COVE ROAD NORTH BILLERICA MA 01862 1 0 0 0 Common stock 2020-06-19 4 A 0 5981 0.00 A 5981 D Non-Qualified Stock Option (Right to Buy) 16.17 2020-06-19 4 A 0 17481 A 2020-06-19 2029-12-13 Common stock 17481 17481 D Received in exchange for a non-qualified stock option to acquire 56,393 shares of Progenics Pharmaceuticals, Inc. ("Progenics") for $5.01 per share, in connection with the merger of Progenics pursuant to the Amended and Restated Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 20, 2020, by and among Lantheus Holdings, Inc. (the "Company"), Plato Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company ("Merger Sub"), and Progenics, pursuant to which Merger Sub merged with and into Progenics, with Progenics surviving as a wholly owned subsidiary of the Company (the "Merger"). /s/ Daniel Niedzwiecki, attorney-in-fact 2020-06-23